HUP0400231A2 - Rákos megbetegedések kezelésében különösen hasznos, immundecepcióra szolgáló eljárások és gyógyszerkészítmények - Google Patents
Rákos megbetegedések kezelésében különösen hasznos, immundecepcióra szolgáló eljárások és gyógyszerkészítményekInfo
- Publication number
- HUP0400231A2 HUP0400231A2 HU0400231A HUP0400231A HUP0400231A2 HU P0400231 A2 HUP0400231 A2 HU P0400231A2 HU 0400231 A HU0400231 A HU 0400231A HU P0400231 A HUP0400231 A HU P0400231A HU P0400231 A2 HUP0400231 A2 HU P0400231A2
- Authority
- HU
- Hungary
- Prior art keywords
- immune
- deception
- cancer
- treatment
- methods
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 abstract 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 abstract 2
- 239000012636 effector Substances 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
A találmány tárgyát egy olyan immunmolekula képezi, mely tartalmaz egyoldható humán I. osztályú MHC effektordomént és az említett oldhatóhumán I. osztályú MHC effektordoménhez kapcsolt célzódomént. Atalálmány továbbá az immunmolekulát kódoló nukleinsavszerkezetekre, azimmunmolekula előállítási eljárására és a molekulát tartalmazókészítményekre vonatkozik. A találmány további tárgya az immunmolekulaalkalmazása egy adott célsejt, különősen rákos sejtek elpusztítására. Ó
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29891501P | 2001-06-19 | 2001-06-19 | |
US10/108,511 US20030017134A1 (en) | 2001-06-19 | 2002-03-29 | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer |
PCT/IL2002/000478 WO2002102299A2 (en) | 2001-06-19 | 2002-06-18 | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0400231A2 true HUP0400231A2 (hu) | 2005-05-30 |
HUP0400231A3 HUP0400231A3 (en) | 2010-11-29 |
Family
ID=26805971
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0400231A HUP0400231A3 (en) | 2001-06-19 | 2002-06-18 | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer |
Country Status (11)
Country | Link |
---|---|
US (1) | US20030017134A1 (hu) |
EP (1) | EP1409547B1 (hu) |
JP (1) | JP5148804B2 (hu) |
CA (1) | CA2451353C (hu) |
CZ (1) | CZ200479A3 (hu) |
DK (1) | DK1409547T3 (hu) |
ES (1) | ES2652017T3 (hu) |
HU (1) | HUP0400231A3 (hu) |
NZ (2) | NZ530656A (hu) |
PL (1) | PL373302A1 (hu) |
WO (1) | WO2002102299A2 (hu) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7645743B2 (en) * | 1999-12-22 | 2010-01-12 | Altermune, Llc | Chemically programmable immunity |
CA2328356A1 (en) * | 1999-12-22 | 2001-06-22 | Itty Atcravi | Recreational vehicles |
US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
WO2001072768A2 (en) * | 2000-03-27 | 2001-10-04 | Technion Research And Development Foundation Ltd. | Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same |
US8022190B2 (en) | 2001-06-19 | 2011-09-20 | Technion Research & Development Foundation Ltd. | Immuno-molecules containing viral proteins, compositions thereof and methods of using |
GB2408507B (en) * | 2003-10-06 | 2005-12-14 | Proimmune Ltd | Chimeric MHC protein and oligomer thereof for specific targeting |
CA2571168A1 (en) * | 2004-06-17 | 2006-01-26 | Mannkind Corporation | Mhc i-binding ssx-241-49 variants |
EP1896498B1 (en) | 2005-06-17 | 2014-12-24 | MannKind Corporation | Epitope analogues |
US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
US7977457B2 (en) * | 2006-05-19 | 2011-07-12 | Teva Pharmaceutical Industries Ltd. | Fusion proteins, uses thereof and processes for producing same |
US8604184B2 (en) * | 2009-05-05 | 2013-12-10 | The United States Of America As Represented By The Secretary Of The Air Force | Chemically programmable immunity |
GB0908613D0 (en) * | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
US20130011394A1 (en) * | 2011-06-22 | 2013-01-10 | Hoffmann-La Roche Inc. | Complexes comprising mhc class i fusion polypeptides and antigen-specific antibodies and methods of use |
US10047345B2 (en) | 2012-02-13 | 2018-08-14 | Gamida-Cell Ltd. | Culturing of mesenchymal stem cells with FGF4 and nicotinamide |
US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
CA2887486A1 (en) * | 2012-11-30 | 2014-06-05 | Roche Glycart Ag | Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class i comprising multi-function proteins |
CN109324190A (zh) | 2012-12-11 | 2019-02-12 | 艾伯特叶史瓦大学爱因斯坦医学院 | 高通量受体:配体鉴定方法 |
CA2889788A1 (en) * | 2012-12-21 | 2014-06-26 | F. Hoffmann-La Roche Ag | Disulfide-linked multivalent mhc class i comprising multi-function proteins |
WO2014127220A1 (en) * | 2013-02-15 | 2014-08-21 | The Johns Hopkins University | Antigen-specific t cell redirectors |
KR102488477B1 (ko) * | 2014-01-21 | 2023-01-13 | 앨버트 아인슈타인 컬리지 오브 메디신 | 신속하고 포괄적인 t-세포 면역 모니터링을 위한 세포 플랫폼 |
AU2017268348A1 (en) | 2016-05-18 | 2018-10-25 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
AU2017266905B2 (en) | 2016-05-18 | 2022-12-15 | Albert Einstein College Of Medicine, Inc. | Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof |
AU2017273147B2 (en) | 2016-06-02 | 2024-06-13 | Immunocore Limited | Dosing regimen for GP100-specific TCR - anti-CD3 SCFV fusion protein |
IL308851A (en) | 2016-12-22 | 2024-01-01 | Cue Biopharma Inc | Multimeric polypeptides modulate T cells and methods for their use |
EP3565829A4 (en) | 2017-01-09 | 2021-01-27 | Cue Biopharma, Inc. | MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE |
CN111010875B (zh) | 2017-03-15 | 2024-04-05 | 库尔生物制药有限公司 | 用于调节免疫应答的方法 |
US20210147550A1 (en) * | 2017-08-18 | 2021-05-20 | Joshua Michael Francis | Antigen-binding proteins targeting shared antigens |
CN111886241A (zh) | 2018-01-09 | 2020-11-03 | 库尔生物制药有限公司 | 多聚体t细胞调节多肽及其使用方法 |
EP3755711A4 (en) * | 2018-02-20 | 2021-11-24 | Technion Research & Development Foundation Limited | IMMUNOTHERAPEUTIC COMPOSITION FOR THE TREATMENT OF CANCER |
MX2022013208A (es) | 2020-05-12 | 2022-11-14 | Cue Biopharma Inc | Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos. |
WO2023126544A1 (en) * | 2022-01-03 | 2023-07-06 | Aarhus Universitet | Proteinaceous compound for generating specific cytotoxic t-cell effect |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5194425A (en) * | 1988-06-23 | 1993-03-16 | Anergen, Inc. | Mhc-mediated toxic conjugates useful in ameliorating autoimmunity |
US5468481A (en) * | 1988-06-23 | 1995-11-21 | Amergen, Inc. | MHC class II-peptide conjugates useful in ameliorating autoimmunity |
US5260422A (en) * | 1988-06-23 | 1993-11-09 | Anergen, Inc. | MHC conjugates useful in ameliorating autoimmunity |
DE3825615A1 (de) * | 1988-07-28 | 1990-02-01 | Behringwerke Ag | Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung |
US5976551A (en) * | 1991-11-15 | 1999-11-02 | Institut Pasteur And Institut Nationale De La Sante Et De La Recherche Medicale | Altered major histocompatibility complex (MHC) determinant and method of using the determinant |
US5837477A (en) * | 1993-01-15 | 1998-11-17 | The United States Of America As Represented By The Department Of Health And Human Services | T cell receptor ligands and methods of using same |
US5820866A (en) * | 1994-03-04 | 1998-10-13 | National Jewish Center For Immunology And Respiratory Medicine | Product and process for T cell regulation |
US5635363A (en) * | 1995-02-28 | 1997-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for the detection, quantitation and purification of antigen-specific T cells |
EP0870040A2 (en) * | 1995-12-29 | 1998-10-14 | Chiron Corporation | Gene delivery vehicle-targeting ligands |
US5869270A (en) * | 1996-01-31 | 1999-02-09 | Sunol Molecular Corporation | Single chain MHC complexes and uses thereof |
JPH11507843A (ja) * | 1996-03-28 | 1999-07-13 | ザ・ジョンズ・ホプキンス・ユニバーシティー | タンパク質の可溶性二価および多価ヘテロ二量体類縁体 |
US6140113A (en) * | 1996-03-28 | 2000-10-31 | The Johns Hopkins University | Polynucleotides encoding molecular complexes which modify immune responses |
US6211342B1 (en) * | 1996-07-18 | 2001-04-03 | Children's Hospital Medical Center | Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function |
US6232445B1 (en) * | 1997-10-29 | 2001-05-15 | Sunol Molecular Corporation | Soluble MHC complexes and methods of use thereof |
US6235445B1 (en) * | 1998-04-15 | 2001-05-22 | Fuji Photo Film Co., Ltd. | Thermal transfer sheet |
GB2339782A (en) * | 1998-06-05 | 2000-02-09 | Philip Michael Savage | Chimeric protein complexes comprising HLA class I antigens |
WO2001072768A2 (en) * | 2000-03-27 | 2001-10-04 | Technion Research And Development Foundation Ltd. | Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same |
AU5532601A (en) * | 2000-04-12 | 2001-10-30 | Univ Rochester | Targeted vaccine delivery systems |
WO2001090198A1 (en) * | 2000-05-24 | 2001-11-29 | Ludwig Institute For Cancer Research | Multicomponent conjugates which bind to target molecules and stimulate cell lysis |
GB0026812D0 (en) * | 2000-11-02 | 2000-12-20 | Isis Innovation | Cancer therapy |
-
2002
- 2002-03-29 US US10/108,511 patent/US20030017134A1/en not_active Abandoned
- 2002-06-18 DK DK02733206.3T patent/DK1409547T3/en active
- 2002-06-18 NZ NZ530656A patent/NZ530656A/en not_active IP Right Cessation
- 2002-06-18 HU HU0400231A patent/HUP0400231A3/hu unknown
- 2002-06-18 JP JP2003504888A patent/JP5148804B2/ja not_active Expired - Fee Related
- 2002-06-18 WO PCT/IL2002/000478 patent/WO2002102299A2/en active Application Filing
- 2002-06-18 NZ NZ581793A patent/NZ581793A/en not_active IP Right Cessation
- 2002-06-18 ES ES02733206.3T patent/ES2652017T3/es not_active Expired - Lifetime
- 2002-06-18 EP EP02733206.3A patent/EP1409547B1/en not_active Expired - Lifetime
- 2002-06-18 CA CA2451353A patent/CA2451353C/en not_active Expired - Fee Related
- 2002-06-18 PL PL02373302A patent/PL373302A1/xx not_active Application Discontinuation
- 2002-06-18 CZ CZ200479A patent/CZ200479A3/cs unknown
Also Published As
Publication number | Publication date |
---|---|
JP5148804B2 (ja) | 2013-02-20 |
CA2451353A1 (en) | 2002-12-27 |
WO2002102299A3 (en) | 2003-11-27 |
DK1409547T3 (en) | 2018-01-08 |
JP2005506058A (ja) | 2005-03-03 |
HUP0400231A3 (en) | 2010-11-29 |
US20030017134A1 (en) | 2003-01-23 |
NZ530656A (en) | 2007-05-31 |
CZ200479A3 (cs) | 2004-11-10 |
PL373302A1 (en) | 2005-08-22 |
NZ581793A (en) | 2010-07-30 |
CA2451353C (en) | 2012-01-17 |
EP1409547A4 (en) | 2007-05-02 |
EP1409547A2 (en) | 2004-04-21 |
EP1409547B1 (en) | 2017-09-20 |
ES2652017T3 (es) | 2018-01-31 |
WO2002102299A2 (en) | 2002-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0400231A2 (hu) | Rákos megbetegedések kezelésében különösen hasznos, immundecepcióra szolgáló eljárások és gyógyszerkészítmények | |
DE69738581D1 (de) | Menschliche dnase i hyperaktive varianten | |
IL176007A0 (en) | Antibodies specific to c35 and pharmaceutical compositions containing the same | |
HUP0401534A2 (hu) | Módosított humán IX. faktor | |
WO2002098358A3 (en) | Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer | |
HUP0401124A2 (hu) | VII koagulációs faktor származékok | |
DE69636937D1 (de) | Durch trans-spaltung erhaltene therapeutische molekule | |
HUP0302352A2 (hu) | SN-38 lipid komplexek és alkalmazásuk | |
MXPA05008222A (es) | Metodos y composiciones para administrar agentes terapeuticos y de diagnostico. | |
AU2003275958A1 (en) | Muteins of tear lipocalin | |
HUP0400659A2 (hu) | Kitinázokkal, kitinázszerű molekulákkal és gyulladásos megbetegedéssel kapcsolatos eljárások, készítmények és reagenskészletek | |
ATE314095T1 (de) | Virusähnliche partikel zur induktion von autoantikörpern | |
AU2002248384A1 (en) | Serpin drugs for treatment of hiv infection and method of use thereof | |
MY140840A (en) | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals | |
CO5660287A2 (es) | Derivados de tetrahidrocarbazol y su uso farmaceutico | |
NO20055209D0 (no) | Peptabody for cancerbehandling | |
PL1654253T3 (pl) | Podstawione pochodne 3-pirolidynoindolu | |
CY1109361T1 (el) | Υποκατεστημενες 4-αμινοκυκλοεξανολες | |
CY1113116T1 (el) | Υποκατεστημενες 4-αμινοκυκλοεξανολες | |
DE602004017871D1 (de) | Zubereitungen zur behandlung von arthritischen erscheinungen | |
ATE355288T1 (de) | Verbindungen und therapeutische methoden | |
HUP0102302A2 (hu) | Heliomicint kódoló gén és alkalmazása | |
HUP9901908A2 (hu) | p16 Expressziós konstrukciók és alkalmazásuk rákterápiában | |
AU2001259353A1 (en) | Novel mutated form of arginine deiminase | |
CY1107231T1 (el) | Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |